about
Lectin of Concanavalin A as an anti-hepatoma therapeutic agentPathogen-Associated Molecular Patterns Induced Crosstalk between Dendritic Cells, T Helper Cells, and Natural Killer Helper Cells Can Improve Dendritic Cell VaccinationCancer immunotherapy via dendritic cellsSynergism from combined immunologic and pharmacologic inhibition of HER2 in vivo.Dendritic cell based tumor vaccination in prostate and renal cell cancer: a systematic review and meta-analysis.Reversal of papilloma growth in rabbits therapeutically vaccinated against E6 with naked DNA and/or vesicular stomatitis virus vectors.Effect of a small molecule BCL-2 inhibitor on immune function and use with a recombinant vaccine.INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect.Immunotherapy of cancer in 2012.Can dendritic cells improve whole cancer cell vaccines based on immunogenically killed cancer cells?From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancerTrial watch: Dendritic cell-based interventions for cancer therapyThe effect of antigen encapsulation in chitosan particles on uptake, activation and presentation by antigen presenting cellsA tumor lysate is an effective vaccine antigen for the stimulation of CD4(+) T-cell function and subsequent induction of antitumor immunity mediated by CD8(+) T cells.Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death.Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.Peptide Based Vaccine Approaches for Cancer-A Novel Approach Using a WT-1 Synthetic Long Peptide and the IRX-2 Immunomodulatory RegimenPolyclonal immune responses to antigens associated with cancer signaling pathways and new strategies to enhance cancer vaccinesA novel immunogenic CS1-specific peptide inducing antigen-specific cytotoxic T lymphocytes targeting multiple myeloma.Dendritic cells in immunotherapy of established cancer: Roles of signals 1, 2, 3 and 4Polarized dendritic cells as cancer vaccines: directing effector-type T cells to tumors.Current immunotherapy for solid tumors.Recent developments in cancer vaccinesDendritic cell-based tumor vaccinations in epithelial ovarian cancer: a systematic review.Various ways to improve whole cancer cell vaccines.Dendritic cells in cancer immunotherapy: vaccines or autologous transplants?Central role of IFNgamma-indoleamine 2,3-dioxygenase axis in regulation of interleukin-12-mediated antitumor immunityImmunosuppressive CD14+HLA-DRlow/- monocytes in prostate cancer.FDG PET scans as evaluation of clinical response to dendritic cell vaccination in patients with malignant melanoma.Immunogenicity of chimeric MUC1-HER2 vaccine against breast cancer in mice.
P2860
Q21284430-4E09E4B0-C3A2-4B82-A609-938D7F60508FQ26765345-6B366541-D7C6-4511-9B7A-C64CED9511DAQ29615444-867036E8-8071-4B64-9991-B13ACBA08C9AQ33798772-439BA6A5-8629-41C3-9AC2-10D3826A8A83Q33886261-C77C3137-3C92-47D5-BBFC-9CD2EC82AA6AQ33940220-56F8C01B-9D80-4620-817F-6121C1DF61F0Q34074715-6A410E76-5DDB-46FA-9FED-33362AB7BD2BQ35136043-8F39FB0F-138C-413D-9D4D-8F9E4AA3C3B0Q36243536-0CBA268A-1FF3-45FF-8468-D9588B2AFCE0Q36255729-B009ED31-3F0E-4FD4-9968-F0DADE5030B5Q36293995-6CF3D121-676A-423C-9D78-9A0DC9D0FA27Q36388529-1F90D359-CF29-4BBA-BAC4-71A4B03C93D2Q36553255-19D91FBE-A82A-41E5-AFB5-634D18D4D238Q36839001-E1B57AB9-29EF-4849-BA23-2E69ABB71775Q36874767-B905E365-81EE-4BCD-B405-C067F1863746Q37074226-56DA493B-4B15-4281-9C43-746A236D1F8AQ37148167-BFFA9B8E-2B89-4016-8A5A-1C1E9F2293C1Q37173925-5F13ED60-3600-4A99-ACE0-231A7AC9BF33Q37284373-FAC79316-6BE4-46F7-81A2-3E631FE8FB5BQ37513871-CF54DD61-91AC-4857-A89B-116A9913CBD1Q37735454-20663365-DD0D-4188-B806-63CF9DCEACD3Q37773274-3592E4DD-3E29-4324-8573-56C937874EC6Q37830226-963CFA19-5C01-4DAA-A6E1-556619A5E3D3Q38059513-B0C8DE81-4F9E-478E-8472-FE3025F294C7Q38206582-1CCD26E4-FE64-4944-8738-5B909F81172BQ41520681-983A4EDF-8AB8-461B-8BB3-81EA770FFD4EQ42130331-8A1C5679-2833-4322-8D2B-08833EE3731DQ42183073-D9DDA623-A1E2-4EDB-B5A9-7C6207368AE8Q46165601-E9A24000-3BD4-41C6-80E5-0043AD595F6FQ49378999-E0DBDF1D-271B-4876-AE9D-6005CD028263
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 28 March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Paradigm shifts in cancer vaccine therapy.
@en
Paradigm shifts in cancer vaccine therapy.
@nl
type
label
Paradigm shifts in cancer vaccine therapy.
@en
Paradigm shifts in cancer vaccine therapy.
@nl
prefLabel
Paradigm shifts in cancer vaccine therapy.
@en
Paradigm shifts in cancer vaccine therapy.
@nl
P2093
P2860
P356
P1476
Paradigm shifts in cancer vaccine therapy
@en
P2093
James L Gulley
Jeffrey Schlom
Philip M Arlen
P2860
P304
P356
10.3181/0708-MR-226
P577
2008-03-28T00:00:00Z